Legal status by country
Is Myostatin legal?
Written by Aaron CuhaReviewed Sep 2026
How Myostatin is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Not a drug; endogenous hormone and research infusion peptide | Not a licensed medicine; research use | Not approved; research use | Not authorized; research use |
| Note | Drugs acting at its receptor are approved. The hormone itself is not a therapeutic. | None recorded | None recorded | None recorded |
US FDA status: Myostatin is an endogenous protein, not a drug. Drugs targeting the pathway are investigational; apitegromab has phase 3 data in spinal muscular atrophy.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.